AGER and neoplasm: In contrast, Azeliragon’s ability to bind directly to RAGE and inhibit multiple ligands of RAGE offers a broader inhibition of the RAGE pathway, which is advantageous given that multiple ligands are implicated in promoting tumor growth, migration, and resistance to therapy via the RAGE pathway [7,18,21,34].